V Bozon
François Rabelais University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by V Bozon.
Journal of Molecular and Cellular Cardiology | 2010
Mickaël Derangeon; V Bozon; Norah Defamie; Nicolas Peineau; Nicolas Bourmeyster; Denis Sarrouilhe; J Argibay; Jean-Claude Hervé
5-hydroxytryptamine-4 (5-HT(4)) receptors have been proposed to contribute to the generation of atrial fibrillation in human atrial myocytes, but it is unclear if these receptors are present in the hearts of small laboratory animals (e.g. rat). In this study, we examined presence and functionality of 5-HT(4) receptors in auricular myocytes of newborn rats and their possible involvement in regulation of gap junctional intercellular communication (GJIC, responsible for the cell-to-cell propagation of the cardiac excitation). Western-blotting assays showed that 5-HT(4) receptors were present and real-time RT-PCR analysis revealed that 5-HT(4b) was the predominant isoform. Serotonin (1 microM) significantly reduced cAMP concentration unless a selective 5-HT(4) inhibitor (GR113808 or ML10375, both 1 microM) was present. Serotonin also reduced the amplitude of L-type calcium currents and influenced the strength of GJIC without modifying the phosphorylation profiles of the different channel-forming proteins or connexins (Cxs), namely Cx40, Cx43 and Cx45. GJIC was markedly increased when serotonin exposure occurred in presence of a 5-HT(4) inhibitor but strongly reduced when 5-HT(2A) and 5-HT(2B) receptors were inhibited, showing that activation of these receptors antagonistically regulated GJIC. The serotoninergic response was completely abolished when 5-HT(4), 5-HT(2A) and 5-HT(2B) were simultaneously inhibited. A 24 h serotonin exposure strongly reduced Cx40 expression whereas Cx45 was less affected and Cx43 still less. In conclusion, this study revealed that 5-HT(4) (mainly 5-HT(4b)), 5-HT(2A) and 5-HT(2B) receptors coexisted in auricular myocytes of newborn rat, that 5-HT(4) activation reduced cAMP concentration, I(Ca)(L) and intercellular coupling whereas 5-HT(2A) or 5-HT(2B) activation conversely enhanced GJIC.
Receptors & Channels | 2004
Emmanuella Di Scala; Ian Findlay; S Rose; Michel Aupart; J Argibay; Pierre Cosnay; V Bozon
In human atrial myocytes, serotonin rather than sympathetic, stimulation is more frequently associated with atrial fibrillation. So does the arrhythmogenic effect of serotonin result from the mechanism of action of the receptor or the context of its action upon cardiac myocytes? The capacity of agonists to produce cAMP followed the sequence 5-HT < Iso < Forskolin to increase ICaL with 5-HT = Iso = Forskolin. The simultaneous application of threshold concentrations of 5-HT and Iso maximally increased ICaL. We will show that the effect of 5-HT upon human atrial myocytes is an imbalance between low production of cAMP and maximal activation of ICaL.
Receptors & Channels | 2004
Emmanuella Di Scala; S Rose; Olivier Herault; J Argibay; Pierre Cosnay; V Bozon
The initial objective of this work was to examine the effects of an antibody (Anti-G21V) directed against the second extracellular loop of human heart 5-HT4 receptors expressed in Chinese hamster ovary (CHO) cells. The antibody anti-G21V had no effect upon either basal cAMP-or 5-HT-evoked increases in cAMP in CHO cells, whereas it had shown an agonist-like effect in COS-7 cells. Analysis of agonist fractions of h5-HT4(e) receptors in CHO and COS-7 cells revealed that equilibrium constant could underlie the different responses of the receptor toward the anti-G21V antibody. Therefore, different expression systems could give rise to functional differences in 5-HT4 receptor behavior.
arXiv: Molecular Networks | 2018
Francesco De Pascali; Aurélie Tréfier; Flavie Landomiel; V Bozon; Gilles Bruneau; Romain Yvinec; Anne Poupon; Pascale Crépieux; Eric Reiter
Follicle-stimulating hormone (FSH) is produced in the pituitary and is essential for reproduction. It specifically binds to a membrane receptor (FSHR) expressed in somatic cells of the gonads. The FSH/FSHR system presents many peculiarities compared to classical G protein-coupled receptors (GPCRs). FSH is a large naturally heterogeneous heterodimeric glycoprotein. The FSHR is characterized by a very large NH2-terminal extracellular domain, which binds FSH and participates to the activation/inactivation switch of the receptor. Once activated, the FSHR couples to Gαs and, in some instances, to other Gα-subunits. GPCR kinases and β-arrestins are also recruited to the FSHR and account for its desensitization, the control of its trafficking and its intracellular signaling. Of note, the FSHR internalization and recycling are very fast and involve very early endosomes (EE) instead of EE. All the transduction mechanisms triggered upon FSH stimulation lead to the activation of a complex signaling network that controls gene expression by acting at multiple levels. The integration of these mechanisms not only leads to context-adapted responses from the target gonadal cells but also indirectly affects the fate of germ cells. Depending on the physiological/developmental stage, FSH elicits proliferation, differentiation, or apoptosis in order to maintain the homeostasis of the reproductive system. Pharmacological tools targeting FSHR recently came to the fore and open promising prospects both for basic research and therapeutic applications. This chapter provides an updated review of the most salient aspects and peculiarities of FSHR biology and pharmacology.
Biochemical Pharmacology | 2007
Emmanuella Di Scala; S Rose; Olivier Herault; J Argibay; Pierre Cosnay; V Bozon
Journal of Molecular and Cellular Cardiology | 2006
A. Fitou; E. Bergöend; D. Gennetay; M. Pingaud; A. Tahir; P. Neville; M. Aupart; M. Marchand; J Argibay; Pierre Cosnay; V Bozon
Congrès Groupe de Reflexion sur la Recherche Cardiovasculaire | 2004
Emmanuella Di Scala; S Rose; D Gennetay; M Pingaud; Pierre Cosnay; J Argibay; V Bozon
“Seven annual meeting on health science and technology” Ecole doctorale santé, sciences et technologie de Tours | 2003
Emmanuella Di Scala; S Rose; D Gennetay; M Pingaud; J Argibay; Pierre Cosnay; V Bozon
“16ème Colloque Biotechnocentre” | 2003
Emmanuella Di Scala; S Rose; D Gennetay; M Pingaud; J Argibay; Pierre Cosnay; V Bozon
Special FEBS 2003, Meeting on signal Transduction | 2003
Emmanuella Di Scala; S Rose; D Gennetay; M Pingaud; J Argibay; Pierre Cosnay; V Bozon